<DOC>
	<DOCNO>NCT00027547</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy . Sometimes transplanted cell reject body 's normal tissue . Mycophenolate mofetil donor white blood cell may prevent happen . PURPOSE : Phase I/II trial determine effectiveness combination chemotherapy total-body irradiation follow peripheral stem cell transplantation treat patient acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Total-Body Irradiation Followed Peripheral Stem Cell Bone Marrow Transplantation Treating Patients With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine one-year disease free survival 40 % day 200 transplant-related mortality le 25 % achieved patient high-risk acute lymphoblastic leukemia complete remission treat nonmyeloablative conditioning regimen comprise fludarabine total body irradiation follow allogeneic peripheral blood stem cell bone marrow transplantation . - Evaluate efficacy toxicity donor lymphocyte infusion treatment minimal residual disease nonmyeloablative allografting patient . OUTLINE : This multicenter study . Patients receive nonmyeloablative conditioning regimen comprise fludarabine IV day -4 -2 total body irradiation ( TBI ) day 0 . Children undergo allogeneic peripheral blood stem cell transplantation ( PBSCT ) bone marrow transplantation TBI day 0 . Adults undergo filgrastim ( G-CSF ) -mobilized allogeneic PBSCT TBI day 0 . Patients also receive graft-versus-host disease ( GVHD ) prophylaxis therapy comprise oral cyclosporine twice daily day -3 56 tapered oral mycophenolate mofetil 5-10 hour transplantation day 0 twice daily day 1-27 . Patients evidence grade 2 great acute GVHD clinically extensive chronic GVHD , GVHD prophylaxis therapy 1-2 week , stable increase minimal residual disease discontinuation GVHD prophylaxis therapy receive donor lymphocyte infusion ( DLI ) IV 30 minute . DLI repeat every 4 week total 3 dos ( necessary ) . Patients without history CNS leukemia patient history CNS leukemia previously treat prophylactic craniospinal irradiation receive methotrexate ( MTX ) cytarabine ( ARA-C ) intrathecally ( IT ) total 2 dos transplantation total 6 dos begin day 32 transplantation . Patients history CNS leukemia previously treat craniospinal irradiation undergo craniospinal irradiation 11 day condition regimen MTX ARA-C IT total 6 dos begin day 32 transplantation . Male patient also undergo testicular radiotherapy 7 day . Patients follow 1 , 2 , 3 , 6 , 12 , 18 , 24 month . PROJECTED ACCRUAL : A total 30 patient ( 20 adult 10 child ) accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute lymphoblastic leukemia ( ALL ) Adult patient must meet 1 follow criterion : Age 50 75 highrisk ALL complete remission ( CR ) ( le 5 % blast morphology bone marrow aspirate absence peripheral blast ) ALL second CR ( CR2 ) great Age 18 50 highrisk ALL first CR ( CR1 ) either ineligible conventional allogeneic transplantation ( base general medical condition ) refuse conventional transplantation Highrisk adult ALL CR1 include patient meet 1 follow criterion : Age 30 NonTcell phenotype Cytogenetic abnormality include ( 9 ; 22 ) , ( 4 ; 11 ) , trisomy 8 , monosomy 7 Failure achieve CR 4 week induction chemotherapy Age 18 50 ALL CR2 great ineligible conventional allogeneic transplantation base general medical condition Age 18 50 highrisk ALL CR2 great refuse conventional allogeneic transplantation Pediatric patient must meet 1 follow criterion : Under age 18 highrisk ALL CR1 ineligible conventional allogeneic transplantation base general medical condition Highrisk pediatric ALL CR1 include patient meet 1 follow criterion : Cytogenetic abnormality ( 9 ; 22 ) WBC least 25,000/mm3 diagnosis ( 4 ; 11 ) patient age 1 age 10 Hypodiploidy ( 45 chromosome ) Failure achieve CR 4 week induction chemotherapy Persistent peripheral blast 1 week induction chemotherapy Under age 18 CR2 great ineligible conventional allogeneic transplantation base general medical condition Age 12 allow approve principle investigator No active CNS disease Availability sibling donor ( exclude identical twin ) HLA genotypically identical least 1 haplotype HLAA , B , C , DRB1 , DQB1 genotypically phenotypically identical PATIENT CHARACTERISTICS : Age : See Disease Characteristics 75 Performance status : Karnofsky 50100 % ( adult ) Lansky 40100 % ( child ) Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : No fulminant liver failure No alcoholic hepatitis No history bleed esophageal varix No grade II great hepatic encephalopathy No hepatic synthetic dysfunction evidence prolongation PT INR great 2.5 No intractable ascites related portal hypertension No bacterial fungal liver abscess No chronic viral hepatitis bilirubin great 5 mg/dL No biliary obstruction bilirubin great 5 mg/dL No concurrent symptomatic biliary disease Renal : Not specify Cardiovascular : Cardiac ejection fraction least 30 % Pulmonary : No requirement supplementary continuous oxygen Other : HIV negative Not pregnant nurse Fertile patient must use effective contraception 1 year study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent posttransplantation growth factor mycophenolate mofetil administration Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
</DOC>